This live web event has ended. Thank you for attending.
Lipid nanoparticle encapsulated RNA (RNA-LNP) vaccines have played a pivotal role in the global response to the COVID-19 pandemic and are now at various stages of development against a wide-range of other infectious diseases. Limited access to potent ionizable lipids, a key component in LNPs, and expertise for formulation and scale-up, present real barriers to entry in this field. To overcome these challenges, we developed and optimized a novel ionizable lipid and a corresponding LNP composition for the delivery of RNA in vaccine applications.
This webinar describes why access to potent ionizable lipids, a key component in LNPs, and expertise for formulation and scale-up are crucial for successful vaccine formulations.
- LNP formulation and physicochemical characteristics with both messenger RNA (mRNA) and self-amplifying RNA (saRNA)
- In vivo immunogenicity of RNA-LNP vaccines against influenza A and SARS-CoV--2
- Overcoming scale-up and process development challenges in vaccine development